在第一阶段试验中,种族和少数民族癌症患者的结果:元分析
Sanjay Goel1,2,3,4, Abdissa Negassa5, Mohammad H Ghalib6
1Department of Medical Oncology, Robert Wood Johnson Medical School, New Brunswick, New Jersey.
JAMA network open
|July 11, 2024
概括
在癌症第一阶段试验中,种族和少数民族患者获得的好处与非西班牙裔白人患者相似. 这项研究强调了针对不同人群的临床试验招生中公平的结果.
科学领域:
- 在瘤学瘤学.
- 临床试验 临床试验
- 健康差异 在健康上的差异
背景情况:
- 种族和少数民族在癌症临床试验中代表性不足,特别是第一阶段的研究.
- 第1期试验为那些在标准治疗中进展的晚期癌症患者提供了关键的治疗选择.
研究的目的:
- 评估一期癌症试验招生对亚洲,西班牙裔和非西班牙裔黑人患者与非西班牙裔白人患者的好处是否可比.
主要方法:
- 对来自单一机构 (1999-2016) 的患者病历进行了回顾性审查.
- 数据包括所有第一阶段癌症试验中的治疗反应,毒性影响和死亡.
- 总体存活率 (OS) 用单变量和多变量时间到事件分析进行评估,遵循PRISMA指南.
主要成果:
- 该研究包括738名患者:197名西班牙裔患者,238名非西班牙裔黑人患者和282名非西班牙裔白人患者.
- 在各组中,中位数的生存期相似:9.6个月 (西班牙裔),8.3个月 (非西班牙裔黑人) 和9.8个月 (非西班牙裔白人) (P=13).
- 与更糟糕的预后相关的因素包括年龄较大和表现不佳;白细胞病与更好的生存状况有关.
结论:
- 与非西班牙裔白人患者相比,西班牙裔和非西班牙裔黑人患者在参与1期癌症试验时表现出类似的益处.
- 结果表明,在这种试验环境中,少数群体的结果是公平的.
- 进一步的研究应侧重于改善早期癌症试验中的少数群体代表性.
更多相关视频
相关概念视频
01:21Cancer Survival Analysis
340
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
340
02:57Targeted Cancer Therapies
7.5K
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
There are several types of targeted therapies against...
7.5K
01:24Kaplan-Meier Approach
123
The Kaplan-Meier estimator is a non-parametric method used to estimate the survival function from time-to-event data. In medical research, it is frequently employed to measure the proportion of patients surviving for a certain period after treatment. This estimator is fundamental in analyzing time-to-event data, making it indispensable in clinical trials, epidemiological studies, and reliability engineering. By estimating survival probabilities, researchers can evaluate treatment effectiveness,...
123
01:20Comparing the Survival Analysis of Two or More Groups
175
Survival analysis is a cornerstone of medical research, used to evaluate the time until an event of interest occurs, such as death, disease recurrence, or recovery. Unlike standard statistical methods, survival analysis is particularly adept at handling censored data—instances where the event has not occurred for some participants by the end of the study or remains unobserved. To address these unique challenges, specialized techniques like the Kaplan-Meier estimator, log-rank test, and...
175
02:49Cancer Therapies
7.6K
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
7.6K
02:50Combination Therapies and Personalized Medicine
4.9K
Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
4.9K